Alain Herrera
Director/Board Member at NANOBIOTIX
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Laurent Levy | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 10 years |
Stephane Depil | F | 51 | 5 years | |
Marc Buyse | M | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | 36 years |
Jan-Eric Österlund | M | 79 | 1 years | |
Joel Plumas | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 10 years |
Mondher Mahjoubi | M | 65 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
Mei Yueh Ho | F | 74 |
Onward Therapeutics SA
Onward Therapeutics SA BiotechnologyHealth Technology Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston. | - |
Magnus Hurst | M | 68 | - | |
Henri Tassenoy | M | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | - |
Patrick Henno | M | - |
EMERCell SAS
EMERCell SAS Pharmaceuticals: MajorHealth Technology EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed. | 11 years |
Damien Tremolet | M | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | - |
Anne-Marie Graffin | F | 63 | 10 years | |
Laurent Lévy | M | 53 | 21 years | |
Enno Spillner | M | 55 | 10 years | |
Petter Lindqvist | M | 72 | - | |
Eric Halioua | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 8 years |
Roger Tell | M | 59 | 5 years | |
Sangwoo Lee | M | 52 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 5 years |
Gary Phillips | M | 58 | 3 years | |
Anne-Juliette Hermant | F | 51 | 5 years | |
Brandon Owens | M | - | - | |
Linda Danielson | F | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | 18 years |
Bart van Rhijn | M | 52 | 3 years | |
Amel Tounsi | M | 43 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
Craig West | M | - | - | |
Margaret Galluzzi | F | - | 5 years | |
Gery Lefebvre | M | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | - |
Jean-Claude Labrune | M | 81 |
Gustave Roussy Foundation
Gustave Roussy Foundation Hospital/Nursing ManagementHealth Services Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life. | - |
Patrick Tricoli | M | - | 10 years | |
Marc Melviez | M | - |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | - |
Louis Kayitalire | M | 66 | 1 years | |
Véronique Denise Lebey Weill | F | 63 |
Gustave Roussy Foundation
Gustave Roussy Foundation Hospital/Nursing ManagementHealth Services Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life. | 13 years |
Jean-Paul Prieels | M | 78 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
Jean Bizzari | M | 69 |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | - |
Olivier Antoine M. Charmeil | M | 59 | 18 years | |
Nathalie Donne | F | - | - | |
François Fontaine | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
Sten Nilsson | M | 76 | - | |
Sébastien Bazin | M | 61 |
Gustave Roussy Foundation
Gustave Roussy Foundation Hospital/Nursing ManagementHealth Services Gustave Roussy Foundation is a leading European cancer center that specializes in the treatment of rare cancers and complex tumors. Gustave Roussy Foundation is located in Villejuif and Chevilly-Larue, France, and has 3,200 health professionals and 4,100 professionals working on its two campuses. The institute provides expert care for all cancers at every stage of life and caters to almost 50,000 patients per year. It is a source of diagnostic and therapeutic advances and integrates research, patient care, and teaching. The institute offers personalized management that combines innovation and a human-focused approach, taking into account care and physical, psychological, and social quality of life. | 8 years |
Lars Erik Lind | M | 83 | - | |
Jérôme Martinez | M | 63 | 3 years | |
Helena Taflin | M | 51 | - |
Connections Chart
Multi-company connection
Former connections
Statistics
Country | Connections | % of total |
---|---|---|
France | 66 | 67.35% |
Sweden | 21 | 21.43% |
Belgium | 7 | 7.14% |
Switzerland | 1 | 1.02% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alain Herrera
- Personal Network